Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 32, 2023 - Issue 7
Submit an article Journal homepage
164
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study

Jinjie Hea Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information
,
Weijuan Dub The Clinical Pharmacology Department, Innovent Biologics (Suzhou), Suzhou, ChinaView further author information
,
Haijing Yanga Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information
,
Jingjing Wanga Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information
,
Chenghang Caib The Clinical Pharmacology Department, Innovent Biologics (Suzhou), Suzhou, ChinaView further author information
,
Qingyang Mab The Clinical Pharmacology Department, Innovent Biologics (Suzhou), Suzhou, ChinaView further author information
,
Nanyang Lia Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information
,
Jicheng Yua Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information
,
Xiaojie Wua Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information
,
Jufang Wua Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information
,
Yuancheng Chena Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaView further author information
,
Guoying Caoa Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaCorrespondence[email protected]
View further author information
&
Jing Zhanga Phase I Clinical Research Center, Huashan Hospital of Fudan University, Shanghai, ChinaCorrespondence[email protected]
View further author information
 show all
Pages 669-675 | Received 02 Apr 2023, Accepted 23 Jun 2023, Published online: 29 Jun 2023

References

  • Touitou I, Kone-Paut I. Autoinflammatory diseases. Best Pract Res Clin Rheumatol. 2008;22(5):811–829. doi: 10.1016/j.berh.2008.08.009
  • Michalek MI, Loring B, John SM, et al. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi: 10.1111/jdv.13854
  • World Health Organization. Global Report on Psoriasis; WHO. 2016 [Cited 2023 Jun 28]. Available from: https://www.who.int/publications-detail-redirect/9789241565189
  • Parisi R, Iskandar IYK, Kontopantelis E, et al. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;m1590. doi: 10.1136/bmj.m1590.
  • Singh S, Taylor C, Kornmehl H, et al. Iconography: psoriasis and suicidality: a systematic review and meta-analysis. Am Acad Dermatol. 2017;77(3):425–40.e2. doi: 10.1016/j.jaad.2017.05.019
  • Janowski K, And SS, Dermatology MJBJIJO. Clinical and psychological characteristics of patients with psoriasis reporting various frequencies of pruritus [J]. Int J Dermatol. 2014;53(7):820–829. doi: 10.1111/ijd.12074.
  • Oppmann B, Lesley R, Blom B, et al. Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12. 2000;13(5):715–725. doi: 10.1016/S1074-7613(00)00070-4
  • Floss DM, Schröder J, Franke M, et al. Insights into IL-23 biology: from structure to function. Cytokine Growth Factor Rev. 2015;26(5):569–578. doi: 10.1016/j.cytogfr.2015.07.005
  • Liu T, Li S, Ying S, et al. The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: from Bench to Bedside. Front Immunol [ J]]. 2020;11:11. doi: 10.3389/fimmu.2020.594735.
  • Bianchi E, Rogge L. The IL-23/IL-17 pathway in human chronic inflammatory diseases – new insight from genetics and targeted therapies. Microbes Infect. 2019;21(5–6):246–253. doi: 10.1016/j.micinf.2019.06.009
  • Megna M, Balato A, Raimondo A, et al. Guselkumab for the treatment of psoriasis. Expert Opin Biol Ther. 2018;18(4):459–468. doi: 10.1080/14712598
  • Sree KS, Sarah GD, Pona A, et al. Tildrakizumab: a Review of Phase II and III Clinical Trials. Ann Pharmacother. 2018;53(4):413–418. doi: 10.1177/1060028018809522
  • Anstey A. Pooled analysis of tildrakizumab for psoriasis. Br J Dermatol. 2018;179(3):E130–E. doi: 10.1111/bjd.16724
  • Li L, Wu Z, Wu M, et al. IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis - ScienceDirect. Int Immunopharmacol. 2020;89:107008. doi: 10.1016/j.intimp.2020.107008
  • Deng R, Iyer S, Theil FP, et al. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs. 2011;3(1):61–66. doi: 10.4161/mabs.3.1.13799
  • Milligan PA, Brown, Brown MJ, et al. Model-Based Drug Development: a Rational Approach to Efficiently Accelerate Drug Development. Clin Pharmacol Ther. 2013;93:502–514. doi: 10.1038/clpt.2013.54
  • Allerheiligen SR, Therapeutics. Impact of modeling and simulation: myth or fact? Clin Pharmacol Ther. 2014;96(4):413–415. doi: 10.1038/clpt.2014.122
  • Marshall SF, Burghaus R, Cosson V, et al. Good Practices in Model-Informed Drug Discovery and Development (MID3): practice, Application and Documentation. Syst Pharmacol. 2016;5(3):93–122. doi: 10.1002/psp4.12049
  • Nayak S, Sander, Sander O, et al. Getting Innovative Therapies Faster to Patients at the Right Dose: impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use. Clin Pharmacol Ther. 2018;103:378–383. doi: 10.1002/cpt.978
  • Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J. 1995;29(3):1039–1048. doi: 10.1177/009286159502900324
  • Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17(10):1278–1283. doi: 10.1023/A:1026451721686
  • Hummel J, McKendrick S, Brindley C, et al. Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat J Appl Stat Pharm Industry. 2009;8(1):38–49. doi: 10.1002/pst.326
  • US Food and Drug Administration. ILUMYA®Prescribing Information. 2018. [Cited 2023 Jun 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf
  • US Food and Drug Administration. TREMFYA® Prescribing Information. 2017. [Cited 2023 Jun 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/-761061s007lbl.pdf.
  • US Food and Drug Administration. SKYRIZI® Prescribing Information. 2019. [Cited 2023 Jun 1]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022-/761105s014lbl.pdf.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.